Viralytics Limited (VLA) has been granted a key patent by US authorities covering the use of Echoviruses for the treatment of all cancers expressing the integrin a2b1 molecule. EVATAK™ is the trade name for Viralytics’ proprietary formulation of the Echovirus Type 1. EV1 attach to the outside of cells, using a specific ‘receptor’ on the cell’s surface (like a key fitting a lock). EV1 uses the receptor, integrin a2b1 to bind and infect target cells. Types of cancer cells that express high levels of the integrin a2b1 molecule on their surface include ovarian, prostate and gastric cancers. Professor Darren Shafren (Chief Scientific Officer and inventor of the technology) said, “The granting of this US patent significantly increases Viralytics’ intellectual property portfolio, which already includes both US and European patents for a subset of Coxsackie A group viruses including CAVATAKTM, our lead product.”
Tags: Cancer treatment, Patent Granted, Viralytics, VLA
